Honing in on the Appeal Process to Improve Access to Anti-VEGF Therapy for Patients with AMD
| Overview / Abstract: |
Step therapy requirements have limited patient access to FDA-approved, anti–vascular endothelial growth factor (VEGF) agents for the treatment of AMD. Prior authorization requests for these therapies are commonly denied. Hence, it is important that clinicians be aware of the approaches to overcome these barriers and implement systematic and clinically supported appeals that ensure uninterrupted anti-VEGF therapy for patients with AMD. In the third module of this CME Outfitters Snack series, expert faculty focus on developing and implementing strategies for appeals in order to reduce treatment delays. |
|
Expiration |
Nov 21, 2020 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME |
|
Format |
Online, Webinar / Webcast / Video |
|
Credits / Hours |
0.5 AMA PRA Category 1 Credit(s)™/contact hours/CEUs |
|
Accreditation |
ACCME, AANP, AAPA, ACPE, MACRA, ABIM |
|
Presenters / Authors / Faculty |
Darius M. Moshfeghi, MD Derek van Amerongen, MD, MS |
|
Sponsors / Supporters / Grant Providers |
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. |
|
Keywords / Search Terms |
CME Outfitters, LLC macular degeneration, optical, ophthalmology, optical disease, AMD, age-related macular degeneration Free CE CME |
|